Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease. Incidence data from the Netherlands has revealed an annual incidence and point prevalence of 0.7 and 4.4 for idiopathic pulmonary arterial hypertension and 2.2 and 15.6 for pulmonary arterial hypertension, respectively, associated with congenital heart disease (CHD) cases per million children. The updated Nice classification for PH has been enhanced to include a greater depth of CHD and emphasizes persistent PH of the newborn and developmental lung diseases, such as bronchopulmonary dysplasia and congenital diaphragmatic hernia. The management of pediatric PH remains challenging because treatment decisions continue to depend largely on results from evidence-based adult studies and the clinical experience of pediatric experts. (J Am Coll Cardiol 2013;62:D117–26) © 2013 by the American College of Cardiology Foundation

Definition

The definition of PH in children is the same as that in adults. Similar to adults, pulmonary vascular resistance (PVR) is currently treated with targeted PAH drugs and may benefit from these new therapies. This review provides an overview of recent information regarding the current approach and diagnostic classification of PAH in children as based on discussions and recommendations from the Pediatric Task Force of the 5th World Symposium on Pulmonary Hypertension (WSPH) in Nice, France (2013).
in response to AVT that determines operability with adequate sensitivity and specificity to predict a favorable long-term outcome. The preponderance of data used for evaluation of operability includes baseline hemodynamics and clinical characteristics (15). In assessing prognosis in IPAH and repaired CHD, AVT may be predictive. The Barst and Sitbon criteria have each been shown to be of predictive value in IPAH in children and adults (12,16,17).

**Classification**

As a modification of the past Dana Point classification (18), the Nice clinical classification of PH further highlights aspects of pediatric disorders, especially in regard to childhood disorders that may be increasingly encountered by specialists treating adults with PH (Table 1). Children with PH who were diagnosed in the neonatal through adolescent age ranges are now surviving into adulthood; thus, a common classification is required to facilitate transition from pediatric to adult services. In addition, goals for improving pediatric classification systems include the need for clarification of disease phenotype, encouraging new thinking on causation and disease pathobiology, enhancement of diagnostic evaluations, improvements in correlations of phenotype and therapeutic responsiveness, and enhancement of clinical trial design. As a result, the Pediatric Task Force recommended several changes for implementation in the WSPH meeting proceedings.

In particular, the Nice classification now includes additional novel genetic disorders causing PAH, including those related to mutations in the following genes: *SMAD 9*, cavolin 1 (19), potassium channel KCNK3 (20), and T-box 4 (small patella syndrome) (21).

Persistent pulmonary hypertension of the newborn (PPHN), due to its particular anatomic and physiological nature, has been moved to a separate subcategory in group 1 to emphasize unique aspects of its timing of onset immediately after birth, time course, and therapeutic strategies. In group 2, congenital and acquired left heart inflow and outflow tract obstruction has been added (22). Lesions in this category include pulmonary vein stenosis, cor triatriatum, supravalval mitral ring, mitral stenosis, subaortic stenosis, aortic valve stenosis, and coarctation of the aorta associated with an increased left ventricular end-diastolic pressure. In group 3, developmental lung diseases have been emphasized due to growing recognition of the important role of abnormal lung vascular growth in the pathogenesis of PH and impaired lung structure in these disorders (Table 2). Congenital diaphragmatic hernia (CDH) and bronchopulmonary dysplasia (BPD) (Fig. 1) have been highlighted due to their relative frequency and the critical role of PH in determining survival and long-term outcomes (23–25). Several other developmental disorders, such as surfactant protein deficiencies and alveolar capillary dysplasia, are now included as relatively rare but important causes of PH (Table 2). In the neonate, these

excluded in the definition of PH. Absolute pulmonary artery pressure falls after birth, reaching levels that are comparable to adult values within 2 months after birth. After 3 months of age in term babies at sea level, PH is present when the mean pulmonary pressure exceeds 25 mm Hg in the presence of an equal distribution of blood flow to all segments of both lungs. This definition does not carry any implication of the presence or absence of pulmonary hypertensive vascular disease (PHVD). In particular, PVR is important in the diagnosis and management of PHVD in children with CHD.

In defining the response to acute vasodilator testing (AVT), it is critical to initially determine the purpose of the test for the care of the individual child. Three separate situations may be evaluated. First, AVT is critical for determining possible treatment with calcium channel blockers (CCBs) in patients with IPAH. Second, AVT may be helpful in the assessment of operability in children with CHD. Third, AVT may aid in assessing long-term prognosis. There is no drug standard for AVT in pediatrics; however, inhaled nitric oxide (dose range 20 to 80 parts per million) has been used most frequently and is advised if available for this purpose (3,4,7–11). In the child with IPAH, a robust positive response during AVT may be used to determine whether or not treatment with a CCB may be beneficial. Use of the modified Barst criteria, which is defined as a 20% decrease in mean pulmonary artery pressure (PAPm) with normal or sustained cardiac output and no change or decrease in the ratio of pulmonary to systemic vascular resistance (PVR/SVR) has been associated with a sustained response to CCBs (12). Although generally used in adult settings, evaluation of the Sitbon criteria (e.g., a decrease in PAPm by 10 mm Hg to a value <40 mm Hg with sustained cardiac output) has not been studied adequately in children with IPAH to determine if these criteria are appropriate, in particular with regard to long-term response (13). In assessing operability in CHD, there is no established protocol for AVT or proven criteria for assessing the response with respect to either operability or long-term outcomes (level C). Although many studies have evaluated retrospective criteria for operability, such as PVR/SVR (9,14), there is no solid evidence to support the absolute mean pulmonary pressure, PVR index, or PVR/SVR...
CHD of any type who develop PHVD. The task force also recognized lesions in which pulmonary vascular disease is likely, but the specific criteria for PH are not met, and thus are not included in the Nice clinical classification. This includes patients with single ventricle physiology who have undergone bidirectional Glenn or Fontan-type procedures (26). In this setting of nonpulsatile flow to the pulmonary arteries, PAP may not be >25 mm Hg; however, significant pulmonary vascular disease can lead to a poor outcome (27). It is anticipated that these recommended changes in the classification of PH will prove to be useful in the diagnostic evaluation and care of patients and design of clinical trials in pediatric PH.

### Etiology

Current registries have begun to examine the etiology and outcome of pediatric PH. In children, idiopathic PAH, heritable PAH, and APAH-CHD constitute the majority of cases, whereas cases of PAH associated with connective tissue disease are relatively rare (1-4,28). Large registries of pediatric PH, including the TOPP (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) registry (4) and the combined adult and pediatric U.S. REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) registry, have been described (3). Of 362 patients with confirmed PH in the TOPP registry, 317 (88%) had PAH, of which 57% were characterized as IPAH or hereditary PAH (HPAH) and 36% as APAH-CHD (4). PH associated with respiratory disease was also noted, with BPD reported as the most frequent chronic lung disease associated with PH. Only 3 patients had either chronic thromboembolic PH or miscellaneous causes of PH. Chromosomal anomalies (mainly trisomy 21) or syndromes were reported in 47 of the patients (13%) with confirmed PH. Many factors may contribute to PH associated with Down syndrome, such as lung hypoplasia, alveolar simplification (which may be worse in the presence of CHD), CHD, changes in the production and secretion of pulmonary surfactant,
elevated plasma levels of asymmetric dimethyl arginine, hypothyroidism, obstructive airway disease, sleep apnea, reflux, and aspiration (29–31).

Another large registry for pediatric PH has been reported from the nationwide Netherlands PH Service (32). In this registry, 2,845 of 3,263 pediatric patients with PH had PAH (group 1), including transient PAH (82%) and progressive PAH (5%). The remaining causes of PH included lung disease and/or hypoxemia (8%), PH associated with left heart disease (5%), and chronic thromboembolic PH (<1%). The most common causes of transient pulmonary hypertension were PPHN (58%) and APAH-CHD (42%). In the progressive PAH cases, APAH-CHD (72%) and IPAH (23%) were common causes. Down syndrome was the most frequent chromosomal disorder (12%), a rate similar to that observed in the TOPP registry. Thus, early registry reports of children with PH provide important insights into the spectrum of pediatric PH; however, these data are likely limited or biased by the nature of referrals and the clinical practice of PH centers participating in the registries (33).

Epidemiology and Survival

Although the exact incidence and prevalence of PH in pediatric population are still not well known, recent registries have described estimates of incidence and prevalence in children with PAH. In the Netherlands registry, the yearly incidence rates for PH were 63.7 cases per million children. The annual incidence rates of IPAH and APAH-CHD were 0.7 and 2.2 cases per million, respectively. The point prevalence of APAH-CHD was 15.6 cases per million. The incidences of PPHN and transient PH associated with CHD were 30.1 and 21.9 cases per million children, respectively (32). Likewise, the incidence of IPAH in the national registries from the United Kingdom was 0.48 cases per million children per year, and the prevalence was 2.1 cases per million (34).

Prior to the availability of targeted PAH therapies, a single-center cohort study showed that the estimated median survival of children and adults with IPAH were similar (4.12 vs. 3.12 years, respectively) (35). Currently, with targeted pulmonary vasodilators, the survival rate has continued to improve in pediatric patients with PAH. Patients with childhood-onset PAH in the combined adult and pediatric U.S. REVEAL registry demonstrated 1-, 3-, and 5-year estimated survival rates from diagnostic catheterization of 96 ± 4%, 84 ± 5%, and 74 ± 6%, respectively (3). There was no significant difference in 5-year survival between IPAH/FPAH (75 ± 7%) and APAH-CHD (71 ± 13%). Additionally, a retrospective study from the United Kingdom has shown the survival in 216 children with IPAH and APAH-CHD (1). The survival rates of IPAH were 85.6%, 79.9%, and 71.9% at 1, 3, and 5 years, respectively, whereas APAH-CHD survival rates were 92.3%, 83.8%, and 56.9% at 1, 3, and 5 years, respectively. In a separate report of IPAH from the United Kingdom, survival at 1, 3, and 5 years was 89%, 84%, and 75%, whereas transplant-free survival was 89%, 76%, and 57% (34). Reports from the Netherlands have shown 1-, 3-, and 5-year survival of 87%, 78%, and 73%, respectively, for patients with progressive PAH (36). Although overall survival has improved, certain patients, such as those with repaired CHD and PHVD, remain at increased risk (1,32,36,37).

Table 3 Clinical Classification of Congenital Heart Disease Associated With Pulmonary Arterial Hypertension

<table>
<thead>
<tr>
<th>Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Eisenmenger Syndrome</td>
<td>Definition of PAH based on mean PAP &gt;25 mm Hg and PVR &gt;3 Wood units $\times$ m².</td>
</tr>
<tr>
<td>2. Left to right shunts</td>
<td>Operable</td>
</tr>
<tr>
<td></td>
<td>Inoperable</td>
</tr>
<tr>
<td>3. PAH with co-incidental CHD</td>
<td></td>
</tr>
<tr>
<td>4. Post-operative PAH</td>
<td></td>
</tr>
</tbody>
</table>

**Diagnosis**

A methodical and comprehensive diagnostic approach is important because of the many diseases associated with PH. Despite this, recent registries have shown that most children do not undergo a complete evaluation (38–40). A modified, comprehensive diagnostic algorithm is shown in Figure 2. Special situations may predispose to the development of PAH and should be considered (41).

**Treatment Goals**

Although many treatment goals and endpoints for clinical trials are similar in adults and children, there are also important differences. As in adults, clinically meaningful endpoints include clinically relevant events such as death, transplantation, and hospitalization for PAH. Further parameters that directly measure how a patient feels, functions, and survives are meaningful and include functional

---

**Figure 2: Pulmonary Arterial Hypertension Diagnostic Work-Up**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Treatment Goals</th>
</tr>
</thead>
<tbody>
<tr>
<td>A methodical and comprehensive diagnostic approach is important because of the many diseases associated with PH. Despite this, recent registries have shown that most children do not undergo a complete evaluation (38–40). A modified, comprehensive diagnostic algorithm is shown in Figure 2. Special situations may predispose to the development of PAH and should be considered (41).</td>
<td>Although many treatment goals and endpoints for clinical trials are similar in adults and children, there are also important differences. As in adults, clinically meaningful endpoints include clinically relevant events such as death, transplantation, and hospitalization for PAH. Further parameters that directly measure how a patient feels, functions, and survives are meaningful and include functional...</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVT</td>
<td>Acute vasodilator testing; CHD = congenital heart disease; CT = computed tomography; CTA = computed tomography angiography; CTD = connective tissue disease; CTEPH = chronic thromboembolic pulmonary hypertension; CXR = chest radiography; DLCO = diffusing capacity of the lung for carbon monoxide; ECG = electrocardiogram; HPAH = heritable pulmonary arterial hypertension; PA = pulmonary artery; PAH = pulmonary arterial hypertension; PAPm = mean pulmonary artery pressure; PAWP = pulmonary artery wedge pressure; PCH = pulmonary capillary hemangiomatosis; PEA = pulmonary endarterectomy; PFT = pulmonary function test; PH = pulmonary hypertension; PVOD = pulmonary veno-occlusive disease; PVR = pulmonary vascular resistance; RHC = right heart catheterization; RV = right ventricular; V/Q = ventilation/perfusion; WU = Wood units.</td>
</tr>
</tbody>
</table>
class and exercise testing; however, there are no acceptable surrogates in children. Although World Health Organization (WHO) functional class is not designed specifically for infants and children, it has been shown to correlate with 6-min walk distance and hemodynamic parameters (1–3,32,34). Further, WHO functional class has been shown to predict risk for PAH worsening and survival in pediatric PH of different subtypes. Although not validated, a functional class designed specifically for children has been proposed (42). Pediatric PAH treatment goals may be divided into those that are for patients at lower risk or higher risk for death (Table 4). As in adults, clinical evidence of right ventricular failure, progression of symptoms, WHO functional class 3/4 (3,34,36,43), and elevated brain natriuretic peptide levels (44–46) are recognized to be associated with higher risk of death. In children, failure to thrive has been associated with higher risk of death (3,34). Abnormal hemodynamics are also associated with higher risk, but the values found to be associated with higher risk are different than those for adults. Additional parameters include the ratio of PAPm to systemic artery pressure, right atrial pressure >10 mm Hg, and PVR index (PVRI) greater than 20 Wood units $\times$ m$^2$ (16,43). In recent pediatric PAH outcome studies, baseline 6-min walk distance was not a predictor of survival, neither when expressed as an absolute distance in meters nor when adjusted to reference values expressed as z-score or as percentage of predicted value (1,34,36,46,47). Serial follow-up of cardiac catheterization in pediatric PH may be beneficial. Maintenance of a vasoreactivity has been shown to correlate with survival (3,12,16). Indications for repeat cardiac catheterization in children with PH include clinical deterioration, assessment of treatment effect, detection of early disease progression, listing for lung transplant, and prediction of prognosis. However, it must be emphasized that cardiac catheterization should be performed in experienced centers able to manage potential complications such as PH crisis requiring extracorporeal membrane oxygenation (40,48–50). Noninvasive endpoints to be further evaluated in children include pediatric functional class as well as z-scores for body mass index (3,34), echocardiographic parameters such as the systolic to diastolic duration ratio (51), tissue Doppler indexes (52–54), eccentricity index (52), tricuspid plane annular excursion (52,55), and pericardial effusion. Pediatric reference values for cardiopulmonary exercise testing in association with outcome are needed (56,57). Development of assessment tools for daily activity measures may be valuable in determining treatment goals. Initial magnetic resonance imaging parameters are promising (58), and pulsatile hemodynamics such as pulmonary arterial capacitance (59,60) require further validation. Novel parameters, such as fractal branching (61), proteomic approaches (62,63), and definition of progenitor cell populations (64–66) are under active study.

**Treatment**

The prognosis of children with PAH has improved in the past decade owing to new therapeutic agents and aggressive
treatment strategies. However, the use of targeted pulmonary PAH therapies in children is almost exclusively based on experience and data from adult studies, rather than evidence from clinical trials in pediatric patients. Due to the complex etiology and relative lack of data in children with PAH, selection of appropriate therapies remains difficult. We propose a pragmatic treatment algorithm based on the strength of expert opinion that is most applicable to children with IPAH (Fig. 3). Treatment of PPHN has recently been reviewed (67,68).

The ultimate goal of treatment should be improved survival and allowance of normal activities of childhood without the need to self-limit. The Nice pediatric PH treatment algorithm was modeled from the 2009 consensus adult PH treatment algorithm and current pediatric experience (69). Background therapy with diuretics, oxygen, anticoagulation, and digoxin should be considered on an individual basis. Care should be taken to not overly decrease intravascular volume due to the pre-load dependence of the right ventricle. Following the complete evaluation for all causes of PH, AVT is recommended to help determine therapy.

In children with a positive AVT response, oral CCBs may be initiated (12,70). Therapy with amiodipine, nifedipine, or diltiazem has been used. Because CCBs may have negative inotropic effects in young infants, these agents should be avoided until the child is older than 1 year of age. In the child with a sustained and improved response, CCBs may be continued, but patients may deteriorate, requiring repeat evaluation and additional therapy. For children with a negative acute vasoreactivity response or in the child with a failed or nonsustained response to CCBs, risk stratification should determine additional therapy (Table 4). Although the specific number of lower- or higher-risk criteria to drive therapeutic choices is not yet known, a greater proportion of either should be considered as justification for therapy. Similar to adults, determinants of higher risk in children include clinical evidence of right ventricular failure, progression of symptoms, syncope, WHO functional class III or IV, significantly elevated or rising B-type natriuretic peptide levels, severe right ventricular enlargement or dysfunction, and pericardial effusion. Additional hemodynamic parameters that predict higher risk include a PAPm to systemic artery pressure ratio >0.75 (16), right atrial pressure >10 mm Hg, and PVRI greater than 20 Wood units × m² (43). Additional high-risk parameters include failure to thrive. In the child with a negative acute vasoreactivity response and lower risk, initiation of oral monotherapy is recommended. Treatment of choice is an endothelin receptor antagonist (bosentan [43,71–77], ambrisentan [78,79]) or phosphodiesterase 5 (PDE5) inhibitor (sildenafil [80–86], tadalafil [87,88]). The STARTS-1 (Sildenafil in Treatment-Naive Children, Aged 1–17 Years, With Pulmonary Arterial Hypertension) and STARTS-2 sildenafil trials have received recent regulatory attention and were actively discussed at the WSPH meeting. STARTS-1 and STARTS-2 were worldwide randomized (stratified by weight and ability to exercise), double-blind, placebo-controlled studies of treatment-naive children with PAH. In these 16-week studies, the effects of oral sildenafil monotherapy in pediatric PAH were studied (84). Children with PAH (1 to 17 years of age; >8 kg) received low- (10 mg), medium- (10 to 40 mg), or high- (20 to 80 mg) dose sildenafil or placebo orally 3 times daily. The estimated mean ± standard error percentage change in pcVO2 for the low-, medium- and high-doses combined versus placebo was 7.7 ± 4.0% (95% CI: −0.2% to 15.6%; p = 0.056). Thus, the pre-specified primary outcome measure was not statistically significant. Peak VO2 only improved with the medium dose. Functional capacity only improved with high dose sildenafil. PVRI improved with medium- and high-dose sildenafil, but mean PAP was lower only with medium-dose sildenafil. As of June 2011, 37 deaths had been reported in the STARTS-2 extension study (26 on study treatment). Most patients who died had IPAH/HPAH and baseline functional class III/IV disease; patients who died had worse baseline hemodynamics. Hazard ratios for mortality were 3.95 (95% CI: 1.46 to 10.65) for high versus low dose and 1.92 (95% CI: 0.65 to 5.65) for medium versus low dose (83). Review of these data by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) resulted in disparate

---

**Table 4. Pediatric Determinants of Risk**

<table>
<thead>
<tr>
<th>Lower Risk</th>
<th>Determinants of Risk</th>
<th>Higher Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Clinical evidence of RV failure</td>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
<td>Progression of symptoms</td>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
<td>Syncope</td>
<td>Yes</td>
</tr>
<tr>
<td>IIJ</td>
<td>WHO functional class</td>
<td>IIIJ</td>
</tr>
<tr>
<td>Minimally elevated</td>
<td>SBNP/NTproBNP</td>
<td>Significantly elevated Rising level</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>Severe RV enlargement/dysfunction</td>
<td>Pericardial Effusion</td>
</tr>
<tr>
<td>Systemic CI &gt;3.0 l/min/m²</td>
<td>Hemodynamics</td>
<td>Systemic CI &lt;2.5 l/min/m²</td>
</tr>
<tr>
<td>mPAP/mSAP &lt;0.75</td>
<td></td>
<td>mPAP/mSAP &gt;0.75</td>
</tr>
<tr>
<td>Acute vasoreactivity</td>
<td></td>
<td>RAP &gt;10 mm Hg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PVRI &gt;20 WU m²</td>
</tr>
</tbody>
</table>
recommendations. Sildenafil was approved by the EMA in 2011 (10 mg 3 times daily for weight <20 kg and 20 mg 3 times daily for weight >20 kg), with a later warning on avoidance of use of higher doses. In August 2012, the FDA released a warning against the (chronic) use of sildenafil for pediatric patients (ages 1 to 17 years) with PAH.

Children who deteriorate on either endothelin receptor antagonist or PDE5 inhibitor agents may benefit from consideration of early combination therapy (add-on or up front). If the child remains in a low-risk category, addition of inhaled prostacyclin (iloprost [10,89–91], treprostinil [11,92]) to background therapy may be beneficial. It is crucial to emphasize the importance of continuous repeat evaluation for progression of disease in children on any of these therapies. In children who are higher risk, initiation of intravenous epoprostenol (11,12,70,90,93–96) or treprostinil (96,97) should be strongly considered. Experience using subcutaneous treprostinil is increasing as well (98). In the child deteriorating with high-risk features, early consideration of lung transplant is important.

Atrial septostomy may be considered in the child with worsening PAH despite optimal medical therapy but should be considered before the later stages with increased risk (99). Features of a high-risk patient for this procedure include high right atrial pressure and low cardiac output. Atrial septostomy may be considered as an initial procedure or before consideration of lung transplant. Surgical creation of a palliative Potts shunt (descending aorta to left pulmonary artery) has been described as a new option for severely ill children with suprasystemic IPAH (100). Serial reassessment of the response to targeted PAH agents remains a critical part of the long-term care in children with PH. Future clinical trials designed specifically for pediatric patients with PH are essential to further optimize therapeutic guidelines.

Conclusions

The incidence and prevalence of IPAH are lower in children than adults. The Nice classification incorporates the growing population of children with developmental lung diseases, such as BPD and CDH. Recent treatment strategies in children have improved their prognosis over the past decade since the introduction of new therapeutic agents, although almost all are based on experience and cohort studies rather than randomized trials. Future pediatric studies are required for development of specific treatment strategies and clinical endpoints for children with PH.

Reprint requests and correspondence: Dr. Dunbar Ivy, Pediatric Cardiology, Children’s Hospital Colorado, 13123 East 16th Avenue, B100, Aurora, Colorado 80045. E-mail: dunbar.ivy@childrenscolorado.org.

REFERENCES

22. Adatai I, Kulik T, Mullen M. Pulmonary venous hypertension or pulmonary hypertension due to left heart disease. Prog Pediatr Cardiol 2009;27:35–42.


Key Words: congenital heart disease • pediatrics • pulmonary hypertension